Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00653068
First received: April 3, 2008
Last updated: August 5, 2014
Last verified: August 2014

April 3, 2008
August 5, 2014
December 2008
April 2015   (final data collection date for primary outcome measure)
  • Event-free survival [ Time Frame: Time to disease progression, disease relapse, occurrence of a second malignant neoplasm, or death from any cause, assessed up to 4 years ] [ Designated as safety issue: No ]
    For statistical evaluation and data reporting, the study cohort can be regarded as comprising four different strata. A one-sided log-rank test with 5% Type I error rate will be used for stratum I. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I. The comparison with Stratum I will be largely descriptive.
  • Overall survival (S) of patients with histologically and/or molecularly diagnosed AT/RT [ Time Frame: Time to death from any cause, assessed up to 4 years ] [ Designated as safety issue: No ]
    The outcome of very young patients (<3 years of age) on this study whose histologic diagnosis is AT/RT will be compared with infants identified as having AT/RT on POG 9233 and CCG 9921. For patients in strata II through IV, Kaplan-Meier estimates of disease control (event-free survival) and overall survival will be computed and compared to that in stratum I.
  • Toxic death [ Time Frame: During and after completion of study treatment ] [ Designated as safety issue: Yes ]
    Treatment-related death is defined as death primarily attributable to complications of treatment.
  • Toxic death, defined as death primarily attributable to complications of treatment [ Designated as safety issue: Yes ]
  • Event-free survival [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00653068 on ClinicalTrials.gov Archive Site
Overall toxicities as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: During and after completion of study treatment ] [ Designated as safety issue: Yes ]
The occurrence of grade 4 ototoxicity, electrolytic wasting (acidosis), hemorrhagic cystitis, non-hematologic toxicity, or gastrointestinal/mucositis toxicity (defined as mucositis toxicity associated with life-threatening consequences).
  • Toxicity and safety [ Designated as safety issue: Yes ]
  • Survival [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation

This phase III trial is studying giving combination chemotherapy together with 3-dimensional conformal radiation therapy and an autologous peripheral blood stem cell transplant to see how well it works in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy or radiation therapy.

PRIMARY OBJECTIVES:

I. To determine the 6-, 12-, and 24-month event-free survival and overall survival of children (birth to 21 years of age) with atypical teratoid/rhabdoid CNS tumors (AT/RT), diagnosed based on histology, immunophenotyping, and modern molecular and immunohistochemical analysis of INI1, treated with surgery, intensive chemotherapy combined with stem cell rescue, and radiation therapy.

II. To compare the outcome of very young patients (under 3 years old) on this study whose histologic diagnosis is AT/RT with infants identified as having AT/RT on POG-9233 and CCG-9921.

SECONDARY OBJECTIVES:

I. To determine the feasibility and toxicity of the proposed chemotherapy regimen in combination with radiation therapy.

II. To contribute tumor samples from which biologic and gene expression data can be developed to yield prognostic indicators and provide direction for future treatment strategies.

III. To develop a clinical and biologic database on which future studies can be based.

OUTLINE: This is a multicenter study. Patients are stratified according to age and tumor histology (infants [< 36 months of age] with tumor histology and immunohistochemical [IH] analysis diagnostic of atypical teratoid/rhabdoid CNS tumors [AT/RT] [stratum 1] vs infants with INI1 mutation only-based diagnosis [i.e., histology is not consistent with AT/RT] vs older children [≥ 36 months of age] with tumor histology and IH analysis diagnostic of AT/RT vs older children with INI1 mutation only-based diagnosis).

INDUCTION THERAPY AND STEM CELL HARVEST: Patients receive vincristine IV on days 1, 8, and 15 and high-dose methotrexate IV over 4 hours on day 1. Beginning 24 hours after the start of methotrexate, patients receive leucovorin calcium orally or IV every 6 hours until the serum methotrexate level is < 0.1 micromoles. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6*. Patients also receive filgrastim (G-CSF) IV or subcutaneously (SC) once daily beginning on day 7 and continuing until ANC recovers. When ANC is > 1,000/μL post nadir, patients receive G-CSF twice daily for stem cell mobilization. Approximately 2-4 days, later peripheral blood stem cells are harvested once daily, as needed, after each course of induction therapy until a total of 6 x 10^6 CD34+ cells/kg have been collected.

Treatment repeats every 21 days for 2 courses. After completion of induction therapy, patients are re-evaluated. Patients with progressive disease are removed from study. Patients with radiographic evidence of residual tumor are encouraged to undergo second-look surgery prior to proceeding to radiotherapy or consolidation therapy; patients with complete response, partial response, or stable disease proceed to radiation therapy or consolidation therapy depending on age, location of the tumor, and initial diagnosis (whether or not disease is disseminated).**

CONSOLIDATION THERAPY AND STEM CELL RESCUE: Within 2-6 weeks after completion of induction therapy or radiation therapy, patients begin consolidation therapy. Patients receive high-dose carboplatin IV over 4 hours and high-dose thiotepa IV over 2 hours on days 1 and 2 and undergo autologous peripheral blood stem cell (PBSC) rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily beginning 24 hours after stem cell infusion and continuing until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.

RADIATION THERAPY: *Before (but after induction therapy) or after consolidation therapy and stem cell rescue, patients undergo 3-dimensional conformal radiotherapy (3D-CRT) to the brain (and the spine if needed) 5 days a week for 5-6 weeks.

NOTE: *The administration of etoposide, cyclophosphamide, and cisplatin are dependant on the prior clearance of methotrexate to a level of < 0.1 micromoles.

NOTE: **Patients with localized posterior fossa tumors and ≥ 6 months of age at the end of induction therapy OR with localized supratentorial tumors at diagnosis and ≥ 12 months of age at the end of induction therapy proceed to radiotherapy followed by consolidation therapy; patients with disseminated disease at diagnosis, patients with localized posterior fossa tumors at diagnosis and < 6 months of age at the end of induction therapy, or patients with localized supratentorial tumors at diagnosis and < 12 months of age at the end of induction therapy proceed to consolidation therapy followed by radiotherapy. Previously collected tumor tissue is analyzed for a mutation in the INI1 rhabdoid tumor suppressor gene and stained for INI1 antibody.

After completion of study treatment, patients are followed periodically for up to 10 years.

Interventional
Phase 3
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Childhood Atypical Teratoid/Rhabdoid Tumor
  • Procedure: autologous hematopoietic stem cell transplantation
    Undergo autologous PBSC rescue
  • Radiation: 3-dimensional conformal radiation therapy
    Undergo 3D-CRT
    Other Names:
    • 3D conformal radiation therapy
    • 3D-CRT
  • Drug: methotrexate
    Given IV
    Other Names:
    • amethopterin
    • Folex
    • methylaminopterin
    • Mexate
    • MTX
  • Drug: leucovorin calcium
    Given IV or orally
    Other Names:
    • CF
    • CFR
    • LV
  • Drug: etoposide
    Given IV
    Other Names:
    • EPEG
    • VP-16
    • VP-16-213
  • Drug: cyclophosphamide
    Given IV
    Other Names:
    • CPM
    • CTX
    • Cytoxan
    • Endoxan
    • Endoxana
  • Drug: cisplatin
    Given IV
    Other Names:
    • CACP
    • CDDP
    • CPDD
    • DDP
  • Biological: filgrastim
    Given IV or SC
    Other Names:
    • G-CSF
    • Neupogen
  • Drug: carboplatin
    Given IV
    Other Names:
    • Carboplat
    • CBDCA
    • JM-8
    • Paraplat
    • Paraplatin
  • Drug: thiotepa
    Given IV
    Other Names:
    • Oncotiotepa
    • STEPA
    • TESPA
    • Tespamin
    • TSPA
  • Drug: vincristine sulfate
    Given IV
    Other Names:
    • leurocristine sulfate
    • VCR
    • Vincasar PFS
  • Other: laboratory biomarker analysis
    Correlative studies
Experimental: Treatment (chemotherapy, 3D-CRT, autologous PBSC)

Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6*; and filgrastim (G-CSF) IV or SC on day 7 until ANC recovers.

Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Before (but after induction therapy) or after consolidation therapy and stem cell rescue, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks.

Interventions:
  • Procedure: autologous hematopoietic stem cell transplantation
  • Radiation: 3-dimensional conformal radiation therapy
  • Drug: methotrexate
  • Drug: leucovorin calcium
  • Drug: etoposide
  • Drug: cyclophosphamide
  • Drug: cisplatin
  • Biological: filgrastim
  • Drug: carboplatin
  • Drug: thiotepa
  • Drug: vincristine sulfate
  • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
70
Not Provided
April 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of CNS atypical teratoid/rhabdoid tumor (AT/RT) or tumors that have a mutation of the INI1 gene (even if the tumor does not have the usual histologic characteristics of AT/RT)

    • Patients with extra neural metastasis (M4) or renal rhabdoid tumors are not eligible
    • Patients with MRI evidence of spinal disease are eligible
  • Must have undergone definitive surgery in the past 31 days
  • Cranial MRI (with and without gadolinium) must be done pre-operatively

    • Post-operatively, cranial MRI (with and without gadolinium) must be done, preferably within 48 hours of surgery or 10-28days after surgery
  • Entire spinal MRI must be obtained either pre-operatively (with gadolinium) or post-operatively (10-28 days after surgery), prior to study enrollment (with and without gadolinium)
  • Life expectancy > 8 weeks
  • ANC > 1,000/μL
  • Platelet count > 100,000/μL (transfusion independent)
  • Hemoglobin > 8 g/dL (RBC transfusions allowed)
  • Creatinine clearance (minimum of 12-24 hour urine collection) or radioisotope GFR ≥ 60mL/min
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
  • AST and ALT < 2 times ULN for age
  • Shortening fraction of ≥ 27% by echocardiogram OR ejection fraction of ≥ 47% by radionuclide angiogram
  • No evidence of dyspnea at rest
  • Pulse oximetry > 94% on room air
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior radiotherapy or chemotherapy except for the following:

    • Patients enrolled on protocol ACNS0334 whose tumors demonstrate the INI1 gene mutation are eligible to transfer to this study even if they have received one course of induction therapy (these patients must be re-consented to treatment and restaged)
    • Prior corticosteroids allowed
Both
up to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada
 
NCT00653068
ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, U10CA098543
Yes
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Alyssa Reddy, MD Children's Oncology Group
Children's Oncology Group
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP